News & Events
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the U.S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor...
READ MORECrinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an...
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports second quarter 2025 financial results and provided a business update on August 7, 2025 at 4:30PM ET.
READ MOREWebcast: Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results
Event Date: August 7, 2025
READ MORECrinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Crinetics announced new data from its clinical development program evaluating once-daily, oral investigational PALSONIFYTM (paltusotine) in acromegaly at ENDO 2025.
READ MORECrinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO – July 11, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results...
READ MORECrinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an...
READ MORECrinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Crinetics announced eight abstracts from its novel clinical development programs will be presented at the Endocrine Society’s Annual Meeting, ENDO...
READ MORECrinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.